Effects of Simvastatin in Prevention of Vasospasm and Delayed Cerebral Ischemia in Nontraumatic Subarachnoid Hemorrhage (Preliminary Data)

Macedo, S; Siqueira, CM Primo de; Siqueira, S; Bello, Y Brum; Dias, Lucas Carvalho

doi:10.1378/chest.10227

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature search strategy yielded a total of 18 studies for analysis, which comprised of randomized controlled trials (RCTs) [16,17,19,20,[36][37][38][39][40][41][42][43], prospective observational cohort studies [15,44] and retrospective observational studies [18,[45][46][47]. This represented 2594 patients.…”

Section: Search Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Dose-Dependent Effects of Statins for Patients with Aneurysmal Subarachnoid Hemorrhage: Meta-Regression Analysis

Prakash

Poonnoose

et al. 2018

World Neurosurgery

View full text Add to dashboard Cite

show abstract

Section: Search Resultsmentioning

confidence: 99%

“…Nine studies (50.0%) were randomized control trials, with blinding of participants and personnel [16,17,19,20,36,38,40,41,43]. Risk of overall bias was considered high in 7 studies (39.0%) [15,37,39,42,[44][45][46], whereas the risk was minimal in 8 studies (44.4%) [16,17,19,20,36,38,40,41].…”

Section: Search Resultsmentioning

confidence: 99%

Dose-Dependent Effects of Statins for Patients with Aneurysmal Subarachnoid Hemorrhage: Meta-Regression Analysis

Prakash

Poonnoose

et al. 2018

World Neurosurgery

View full text Add to dashboard Cite

show abstract

Cholesterol-reducing agents for aneurysmal subarachnoid haemorrhage

Liu

Zhang

et al. 2013

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundCerebral vasospasm and related delayed ischaemic deficits (DIDs) occur in about 17% to 40% of patients with aneurysmal subarachnoid haemorrhage (SAH) and lead to a poor outcome. Cholesterol-reducing agents might improve unfavourable outcomes. ObjectivesTo assess the effects of cholesterol-reducing agents for improving outcomes in patients with aneurysmal SAH. Search methodsWe searched the Cochrane Stroke Group Trials Register (May 2012), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 5), MEDLINE (1948 to May 2012) and EMBASE (1980 to May 2012. We also searched three Chinese databases: SinoMed, CNKI and VIP (May 2012). In an effort to identify further published, ongoing and unpublished trials we searched relevant clinical trials and research registers (May 2012), contacted pharmaceutical companies and investigators known to be involved in previous trials and screened the reference lists of all relevant articles identified. Selection criteriaWe included randomised controlled trials (RCTs) that compared cholesterol-reducing agents with control or placebo treatment in participants with aneurysmal SAH. Data collection and analysisTwo review authors independently applied the inclusion criteria, reviewed the relevant trials and extracted data. We did not perform meta-analysis as we only included one RCT in the review. Main resultsWe included one study in which 39 patients received either simvastatin (80 mg daily; n = 19) or placebo (n = 20) for 14 days. The incidence of DIDs (secondary outcome) was 26% (5/19) in the simvastatin group versus 60% (12/20) in the placebo group (risk ratio (RR) 0.44, 95% confidence interval (CI) 0.19 to 1.01, P = 0.05). This means that, in this study, simvastatin had no effect on DIDs. 1 Cholesterol-reducing agents for aneurysmal subarachnoid haemorrhage (Review)

show abstract

Effects of Simvastatin in Prevention of Vasospasm and Delayed Cerebral Ischemia in Nontraumatic Subarachnoid Hemorrhage (Preliminary Data)

Cited by 2 publications

References 0 publications

Dose-Dependent Effects of Statins for Patients with Aneurysmal Subarachnoid Hemorrhage: Meta-Regression Analysis

Dose-Dependent Effects of Statins for Patients with Aneurysmal Subarachnoid Hemorrhage: Meta-Regression Analysis

Cholesterol-reducing agents for aneurysmal subarachnoid haemorrhage

Contact Info

Product

Resources

About